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with a CD4 cell count of 20/pL. He was receiving 
prophylaxis against Pneurnocystis carinii with 160 mg 
trimethoprim/800 mg sulfamethoxazole daily, and 
zidovudine 250 mg twice daily. Elevated temperature 
(38.5OC) was the only abnormality detected on 
examination, and the patient did not appear to be 
severely ill. A chest X-ray revealed an infiltrate in the 
right middle lobe with abscess formation and hilar 
lymphadenopathy. Sputum and bronchoalveolar lavage 
(BAL) cultures yielded growth of Gram-positive cocco- 
bacilli which were identified as R. equi by conventional 
biochemical tests. Diagnosis was confirmed by direct 
sequencing of the small ribosomal subunit RNA. Disk 
difision tests and minimum inhibitory concentration 
(MIC) determination by the broth microdilution 
method (National Committee for Clinical Laboratory 
Standards) showed that the primary isolate was suscep- 
tible to gentamicin, ofloxacin/ciprofloxacin, erythro- 
mycin, and vancomycin, but was only intermediately 
susceptible to amoxicillin/sulbactam (Table 1). On  this 
basis, initial therapy with oral amoxicillin/sulbactam 
was changed to oral ciprofloxacin 500 mg twice-daily. 
The patient's clinical response was excellent and, as the 
X-ray abnormalities had resolved, therapy was stopped 
after 4 weeks. 
One month later he was readmitted with a non- 
productive cough and low fever. A computerized 
tomogram (CT) scan of the thorax revealed a new 
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Interest in effective treatment of Rhodococcus equi 
infections is increasing as this opportunistic pathogen is 
more frequently isolated from immunocompromised 
patients. Antibiotic therapy of pulmonary or dissemi- 
nated infections has remained difficult, and relapses 
after termination of chemotherapy are common. This 
has prompted a call for secondary prophylaxis in 
immunocompromised patients [l]. We report here a 
severe case of R. equi pneumonia in an AIDS patient 
that responded well to intravenous antibiotic therapy. 
However, relapse occurred even while the patient was 
on continuing oral rifampin/erythromycin prophylaxis. 
A 33-year-old HIV-infected patient was admitted 
with a productive cough of 2 months' duration, fever liquefaction of a lobe There are 
(39.5 "c) 2nd night Sweats for 1 week, and 3 kg weight 
Figure 1 Thorax CT scan (5 July 1994) showing 
smaller infiltrates in the right lower lobe and in the anterior - 
loss. The patient's stage of HIV disease was CDC B3, upper left lobe. 
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Table 1 Susceptibility pattern of the Rhodococcus equi isolate 
MIC microbroth 
Antimicrobial agent Disk &sion o l g / 4  
Ampi&n/sulbactam i 16/8 i 
Imipenem r 1 S 
Gentamicin s -  2 S 
Clindamycin i 0.5 S 
Erythromycin S 0.5 S 
Vancomycin S 0.25 S 
Rifampicin S 0.25 S 
Ciprofloxacin S 0.5 S 
r=resistant; i=interme&te; s=susceptible; as defined by NCCLS. 
Figure 2 Thorax CT scan (4 October 1994) showing 
contraction of the lateral segment of the middle lobe, and 
complete resolution of the smaller infiltrates in the other 
segments. 
cavitating process in the right middle lobe, abscess 
formation and recent infiltrates in the right lower 
lobe and left upper lobe (Figure 1). R. equi was again 
isolated f b m  BAL. cultures. Intravenous combination 
therapy with vancomycin 1 g twice-daily, rifampicin 
600 mg twice-daily and erythromycin 1 g three times 
daily was instituted. A control CT scan showed 
some resolution of the abscess, regression of infiltrates 
and contraction of the cavitation. The patient was 
discharged after 7 weeks. Long-term prophylactic 
treatment with oral rifampicin 600mg twice-daily 
erythromycin 1 g three times daily was continued. The 
patient was followed in our outpatient clinic on a 
monthly basis. Throughout the course of his illness the 
patient has proved reliable. At each clinic visit he 
confirmed that he had taken the drugs as prescribed. 
Repeated CT scans showed further regression of the 
infiltrates and contraction of the middle lobe cavitation 
(Figure 2). Four months after discharge the patient was 
in a good condition. 
Within the following month, however, he again 
experienced insidious onset of fatigue, non-productive 
cough and weight loss. However, a CT scan of the 
thorax showed no change. While he was s t i l l  on oral 
antibiotic treatment, R. equi was again isolated f b m  
BAL culture. Comparative analysis of Kirby-Bauer 
zone sizes and MICs revealed no change in the 
antibiotic susceptibility pattern. Intravenous therapy 
with vancomycin, rifampicin and erythromycin was 
reinitiated, resulting in clinical improvement within 
10 days. Because of the relapsing pneumonia under 
antimicrobial prophylaxis, surgical resection of the 
middle lobe was performed. The patient has now been 
relapse-fiee for more than 12 months. 
R. equi is an emerging opportunistic pathogen 
for which the most effective therapeutic regimen 
remains to be established. From the first report in an 
AIDS patient in 1986 [2] undll991, only 11 cases were 
reported [3]. Today the number exceeds 60 [l]. The 
clinical symptoms, fever, productive cough and pleuritic 
chest pain, develop very slowly and this often leads to 
a delay in diagnosis. Even after the correct diagnosis 
has been established, infections by R. equi have been 
notoriously difficult to treat and mortality remains high 
[1,4]. In vitro most R. equi isolates are susceptible to 
a wide range of antibiotics [4,5]. However, drug resist- 
ance as well as clinical relapse occur fiequently under 
monotherapy and this has led to recommendations for 
combination therapy [1,4]. Some investigators have 
reported the successful antibiotic treatment of R. equi 
infections by combinations of imipenem and a glyco- 
peptide [6,7]. In view of the chronic immuno- 
deficiency in our patient, an oral prophylactic regimen 
that included a macrolide [8] seemed mandatory. But 
even the combination of erythromycin and rifampicin, 
which penetrates phagocytic cells, did not prevent a 
second relapse. This case demonstrates once more that 
regimens comprising erythromycin and rifampicin can 
be effective for treatment of the infection. However, 
prevention of relapse in immunocompromised patients 
remains a difficult task. Relapse in our case was not the 
consequence of acquired resistance to the administered 
antibiotics. Intensive follow-up care and constant 
alertness with regard to a relapse is needed for the 
management of this infection in chronically immuno- 
compromised patients. 
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Intravenous penetration of fluconazole during 
endophthalmitis 
Clin Microbiol Infect 1997; 3: 143-144 
A recent article by Akler et al. summarized 27 cases of 
fluconazole-treated candidal endophthalmitis reported 
in the Enghsh language literature [l]. Fluconazole was 
the sole therapy in 14 patients, and a favorable outcome 
was obtained in 15 of 16 eyes, including five infections 
that were complicated by vitreitis; however, ocular 
penetration of fluconazole was not evaluated. Although 
the high vitreous penetration of fluconazole is generally 
considered to be responsible for the favorable clinical 
outcome, data on vitreous fluconazole concentrations 
in humans have been reported only twice [2]. We 
have assessed fluconazole penetration into the vitreous 
humor of a patient with endophthalmitis. 
A 27-year-old male heroin addict, weighing 78 kg, 
having normal renal function, was hospitalized in 
August 1994 for blurred vision in the left eye. Ocular 
examination revealed chorioretinal lesions compatible 
with candidal endophthalmitis and vitreitis. Angio- 
graphy confirmed the diagnosis, but direct examination 
and mycologic cultures of the vitreous humor remained 
negative. Treatment consisted of four intravitreous 
injections of amphotericin B at 48-h intervals and 
fluconazole 200 mg twice-daily intravenously for 1 
month and then orally for 2 months. Vitrectomy was 
performed in the third week because of severe vitreitis. 
Two vitreous samples (days 4 and 11) and one serum 
sample (day 7) were obtained about 3 h after the pre- 
vious dose. Fluconazole concentrations were measured 
by reverse-phase liquid chromatography with absor- 
bance detection at 260 nm, either by direct injection of 
the vitreous humor samples or after liquid-liquid 
extraction in the case of the plasma samples. The 
vitreous fluconazole concentrations on days 4 and 
11 were 10.4 and 11.9 mg/L, respectively, while the 
plasma concentration on day 7 was 15.0 mg/L. The 
retina of the infected eye became detached in the 
fifth week. The infection resolved completely and no 
relapse had occurred after more than 10 months of 
In samples taken 3 h after drug administration, the 
vitreous fluconazole concentration was 69-79% of that 
measured in plasma. These results are very similar 
to those reported earlier [2]. Since the fluconazole 
elimination half-life is about 30 h, the steady state 
should have been attained by day 5 of treatment. 
Theoretically if fluconazole penetration into vitreous 
humor were accomplished solely by passive diffusion, 
its vitreous concentration at steady state would be equal 
to that of the free fraction in plasma (89% in humans 
with normal renal function). The difference from the 
measured values is small and probably not significant. 
Therefore, fluconazole-protein binding may be a 
major factor controlling drug penetration into vitreous 
humor. This possibility is important because fluco- 
nazole-protein binding has been shown to depend on 
the al-acid glycoprotein level and to be increased from 
11% in normal subjects to 22% in chronic renal failure 
patients treated by hemodialysis [3], and this enhanced 
protein binding could result in lower fluconazole 
penetration into the eye. Although no relationship has 
been established between the fluconazole concen- 
tration in body fluids and in vivo antifungal activity, 
indirect arguments suggest that such a relationship 
does exist for other azole compounds, such as keto- 
conazole [4] and itraconazole [5]. 
follow-up. 
